ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE post-market surveillance study.
The study is dedicated to further advancement of use of the ArtVentive EOS™ embolization device in treating venous and arterial cases where the precise placement and immediate, efficient vessel embolization are paramount.
The first Study case was performed at The University Hospital, Leuven, Belgium, where Dr. Geert Maleux successfully treated a patient with the ArtVentive EOS™ device. Dr. Maleux, Professor in the Department of Radiology stated, "The ArtVentive EOS™ device enhances our ability to treat challenging embolization cases.
"It offers immediate and complete occlusion. The operator can have confidence that the target vessel is occluded. The ArtVentive EOS™ technology allows for shorter procedure times and potentially reduced radiation exposure for both the physician and patient."
"With new experience and a growing body of evidence, we at ArtVentive are very confident about the progress of the ArtVentive embolization devices in the markets in Europe and looking forward to launching the EOS™ for commercial use in the US," said Dr. Leon Rudakov, President and CTO of ArtVentive.
"We expect to continue developing our extensive pipeline of new coming products which may effect the entire embolization market in a very positive and decisive way."
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is a medical device company focused on developing, manufacturing and globally marketing a family of devices and deepening its already established intellectual property portfolio.
The ArtVentive EOS™ device is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network.